All Stories

Biohaven’s biopolar candidate fails to improve mania in pivotal trial

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial.

Mar 4, 2025 - 08:57
 0
Biohaven’s biopolar candidate fails to improve mania in pivotal trial
Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial.
Read More

Tags:

Previous Article

Vingroup and global investment firm JTA Investment Qatar signed MOU for strategi...

Next Article

Breakfast costs climb as shop price inflation records biggest monthly jump

Related Posts

FDA approves Medtronic’s adaptive deep-brain stimulator for Parkinson’s disease

FDA approves Medtronic’s adaptive deep-brain stimulator...

Feb 24, 2025  0

Grifols, through pioneering plasma research, looks to reveal early warning signs of Parkinson's

Grifols, through pioneering plasma research, looks to r...

Feb 14, 2025  0

Inventiva lays off 50% of staff to go all-in on MASH drug

Inventiva lays off 50% of staff to go all-in on MASH drug

Feb 11, 2025  0